Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis Read more about Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
Amgen To Present New Data At 22nd Congress of the European Hematology Association Read more about Amgen To Present New Data At 22nd Congress of the European Hematology Association
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients Read more about FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society Read more about Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society
Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference Read more about Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab Read more about Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe Read more about Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 Read more about Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017 Read more about Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge Read more about Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge
